Top
US_Flag An official website of the United States government Here's how you know
GOV

The .gov means it's official.

Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.

LOCK

The site is secure.

The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

 
U.S. Food & Drug Administration
Continuing Education and Accreditation
Division of Learning and Organizational Development
Center for Drug Evaluation and Research

Online Learning

Select the activity title to enroll in online learning activities. Learners must complete all educational content and the course evaluation to earn CE credit.
 
 

Search
50 matches found
Title Type
FDA’s Role in Postmarketing Drug Safety Surveillance Enduring Material 
How FDA and ISMP Utilize Medication Error Reports to Improve Drug Safety Enduring Material 
Overview of Expanded Access (EA) Program and EA eRequest Site Enduring Material 
Biosimilar and Interchangeable Biosimilars: Review of Scientific Concepts, Case Studies, and Resources Enduring Material 
Fraudulent Products – Hidden Ingredients and Unproven Claims in Products Marketed as Dietary Supplements Enduring Material 
Enhanced Drug Distribution Security: 2023 and Beyond Enduring Material 
Safety Labeling Changes for Leukotriene Receptor Antagonists and Decisions Behind a Boxed Warning Enduring Material 
FDA’s Office of Orphan Products Development (OOPD) – An Overview and Update Enduring Material 
The Ins and Outs of Prescription Drug Labeling Enduring Material 
Counseling Patients on Generic Drugs Enduring Material 
Pregnancy and Lactation Medication Information for the Healthcare Provider Enduring Material 
FDA Drug Information Resources and Applicability to Health Care Professionals Enduring Material 
Reporting and Public Viewing of Individual Case Safety Reports (ICSRs) Enduring Material 
Drug Shortages: Root Causes and Potential Solutions Enduring Material 
Engaging Providers to Address Knowledge Gaps on Medication Use in Pregnancy and Lactation -- Enduring Material Enduring Material 
Development and U.S. Regulation of Preventive Vaccines Enduring Material 
Understanding Generic Narrow Therapeutic Index Drugs Enduring Material 
The Safety Evaluation and Surveillance of Generic Drugs Enduring Material 
Frequently Asked Questions about Labeling for Prescription Medicines Enduring Material 
Assessment of Stromal Tumor-Infiltrating Lymphocytes Enduring Material 
Cannabis and Cannabis-Derived Products – For Healthcare Practitioners Enduring Material 
PCOS Revisited: Diagnosis, Management, and Future Needs Enduring Material 
Rare Diseases - Challenges and Progress in Drug Development Enduring Material 
FDA Drug Topics: How to Avoid Medication Errors with Pen Injectors Enduring Material 
Biosimilars: A Review of Scientific, Regulatory, and Clinical Considerations for Health Care Providers Enduring Material 
Q&A with FDA Podcast: Expanded Access with Dr. Jacqueline Corrigan-Curay Enduring Material 
Regulatory Framework for Human Drug Compounding Enduring Material 
Naltrexone Injection for Opioid Use Disorder - FDA’s Efforts to Reduce Medication Errors Enduring Material 
Q&A with FDA Podcast: A Step Forward in the Treatment of Opioid and Alcohol Dependence with Dr. Iilun Murphy and Dr. Marta Sokolowska Enduring Material 
Q&A with FDA Podcast: FDA takes steps to decrease barriers for overdose reversal agents with Dr. Marta Sokolowska Enduring Material 
Q&A with FDA Podcast: Navigating the World of Online Pharmacies with CDR Lysette Deshields Enduring Material 
Q&A with FDA Podcast: CURE ID, A Tool for Clinicians to Report New Uses of Existing Drugs with Heather Stone and Dr. Marco Schito Enduring Material 
Q&A with FDA Podcast: Drug Shortages with CDR Emily Thakur Enduring Material 
Hyperemesis Gravidarum: New Research and Insights Enduring Material 
Bringing Clinical Research to Patients Enduring Material 
Advancing Transparency and Regulatory Science Activities on the Risk Evaluation and Mitigation Strategy (REMS) Enduring Material 
An Overview of FDA’s Project Facilitate Oncology Expanded Access Program Enduring Material 
Q&A with FDA Podcast: Generics-at-a-Glance with Dr. Sarah Ibrahim Enduring Material 
Q&A with FDA Podcast: MedWatch, Your Report Can Make a Difference with Dr. Gerald Dal Pan Enduring Material 
Q&A with FDA Podcast: FDA’s Overdose Prevention Framework with Dr. Marta Sokolowska Enduring Material 
Q&A with FDA Podcast: Clinical Trial Basics with Dr. Robert Temple Enduring Material 
Q&A with FDA Podcast: Conversation on Paxlovid with Dr. John Farley Enduring Material 
Q&A with FDA Podcast: Medication Health Fraud and Avoiding Medication Scams with Cynthia Ng Enduring Material 
Q&A with FDA Podcast: The Current Status of Oral Phenylephrine as a Nasal Decongestant with Dr. Theresa Michele and Dr. Ilisa Bernstein Enduring Material 
FDA Drug Safety Podcast: Update on FDA’s ongoing evaluation of reports of suicidal thoughts or actions in patients taking a certain type of medicines approved for type 2 diabetes and obesity Enduring Material 
FDA Drug Safety Podcast: FDA updating warnings to improve safe use of prescription stimulants used to treat ADHD and other conditions Enduring Material 
FDA Drug Safety Podcast: FDA warns of rare but serious drug reaction to the antiseizure medicines levetiracetam (Keppra, Keppra XR, Elepsia XR, Spritam) and clobazam (Onfi, Sympazan) Enduring Material 
FDA Drug Safety Podcast: FDA adds Boxed Warning for increased risk of severe hypocalcemia in patients with advanced chronic kidney disease taking osteoporosis medicine Prolia (denosumab) Enduring Material 
FDA Drug Safety Podcast: FDA updates prescribing information for all opioid pain medicines to provide additional guidance for safe use Enduring Material 
FDA Rare Disease Day 2024: Clinical Trial Foundations and Future Directions Enduring Material 
Back To Top